Will We Never Get Cheery News from the IP Team?

In a perspectives essay posted on Venture Beat, Sergio Garcia and Michael Davis-Wilson from law firm Fenwick & West discuss the current patent landscape in light of the Supreme Court's ruling this year in MedImmune v. Genentech, which they say "effectively paved the way for more frequent patent challenges that could disadvantage smaller companies and organizations." That's especially relevant for this field. "The post-MedImmune environment presents an acute challenge for small biotech companies and universities," the authors write. "These organizations generally have limited funds to fight patent lawsuits and might therefore face stepped-up legal attacks on their patents."